Ocular Therapeutix shifts SOL-R endpoint timing, keeps AXPAXLI NDA on track for Q4 2026
Ocular reported a September pre-NDA meeting with FDA, a SOL-R primary endpoint moved to Week 40, and cash of $530.6 million as of September 30, 2026.
FDA, ClinicalTrials.gov, SEC filing (8)